Figures computed from official regulatory filings — .
Analysttarget 3.33 USD (+658%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 1.43% · institutions 0.05% · short 9.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Vaxart, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
84 buys273 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Finney Kevintrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| Finney Kevintrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wheadon David E. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Watson W. Marktrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BREITMEYER JAMES B | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Watson W. Marktrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HERON ELAINE J | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BREITMEYER JAMES B | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wheadon David E. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HERON ELAINE J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Watson W. Marktrack record | Buy | $6.5K | conv 30 | SEC |
| Grasman Jeroen Nicolaas | Other | $19.2K | SEC |
| BREITMEYER JAMES B | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BREITMEYER JAMES B | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tucker Sean | Other | $2.6K | SEC |
| Cummings James F. | Other | $2.1K | SEC |
| Cummings James F. | Other | $21.1K | Unusual size | SEC |
| Berg Edward B | Other | $25.1K | Unusual size | SEC |
| Lo Steven | Other | $87K | Unusual size | SEC |
| Tucker Sean | Other | $25.1K | Unusual size | SEC |
| Lo Steven | Other | $14.1K | SEC |
| Tucker Sean | Other | $5.1K | SEC |
| Berg Edward B | Other | $5.1K | SEC |
| Cummings James F. | Other | $4.3K | SEC |
| Cummings James F. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |